ArticleInternational journal of molecular sciences2025
Evaluation of Inflammatory Markers in Perception Disorders in Major Psychiatric Pathology.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Social Support and Locus of Control in Subclinical Eating-Disorder Tendencies in a Romania-Based Convenience Sample.Diseases (Basel, Switzerland) · 2026Article
- Review
- HPT Axis Dysregulation in Mood and Anxiety Disorders: The Clinical Utility of Routine Hormonal Dosing in Psychiatric In-Patients.Diseases (Basel, Switzerland) · 2026Article
- Rumination as a Mediator Between Intolerance of Uncertainty and Online Health Anxiety, Moderated by Medical History.Diseases (Basel, Switzerland) · 2026Article
- Emerging Neurobiological and Therapeutic Insights into Schizophrenia: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Romanian male patients with the dual diagnosis of schizophrenia and alcohol use disorder: a prospective study of clinical, social, and treatment-related factors affecting quality of life.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the role of inflammatory markers in perception disorders associated with major psychiatric pathology, focusing on schizophrenia and acute psychotic disorder. Guided by the vulnerability-stress-inflammation model, this research explores how genetic predispositions, maternal immune activation, and chronic low-grade neuroinflammation contribute to disease onset and progression. A sample of 135 patients (69 with schizophrenia and 66 with acute psychotic disorder) admitted to a psychiatric hospital between October 2024 and February 2025 was analyzed. Demographic and clinical data, along with biological markers-such as white blood cells, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR)-were assessed. Results indicated elevated median values for SII, CRP, and MLR, with statistically significant differences compared to normal reference ranges, suggesting persistent systemic inflammation in psychotic disorders. While acute psychotic disorders showed wider value ranges, schizophrenia patients demonstrated higher median levels, consistent with chronic inflammation. No significant differences were observed between the two groups after Bonferroni correction, though CRP values suggested a trend toward greater inflammation in schizophrenia. These findings reinforce the inflammatory hypothesis of psychosis and highlight the potential of biomarkers to refine diagnosis, guide treatment strategies, and support future research into immunomodulatory therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.